TD Cowen raised the firm’s price target on Acadia Pharmaceuticals to $28 from $24 and keeps an Outperform rating on the shares. The analyst noted they announced FDA approval for Daybue, their synthetic analog of IGF-1 for Rett Syndrome, with a broad, clean label. Daybue is expected to officially launch at end of April with a net annual average price of roughly $375k, along with Acadia Connect, a patient/caregiver/HCP education and financial assistance hub.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on ACAD:
- Acadia Pharmaceuticals price target raised to $21 from $19.40 at Citi
- Acadia Pharmaceuticals price target raised to $28 from $25 at H.C. Wainwright
- Acadia Pharmaceuticals announces FDA approval of DAYBUE for Rett syndrome
- Acadia Pharmaceuticals price target raised to $24 from $20 at Canaccord
- This ETF Has 67% Upside Potential, According to Analysts